NCT06858657View on ClinicalTrials.gov

A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK44459 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 17, 2024

Primary Completion Date

November 18, 2024

Study Completion Date

December 20, 2024

Conditions

Healthy

Interventions

DRUG

HSK44459

Dose 1 to Dose 5

DRUG

placebo

dose 1 to dose 5

Trial Locations (1)

Unknown

Nanjing Drum Tower Hospital, Nanjing

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT06858657 - A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK44459 in Healthy Subjects | Biotech Hunter | Biotech Hunter